BRPI0516181A - composto e sais farmaceuticamente aceitáveis do mesmo, composição farmacêutica, e, métodos para tratar trombose em um indivìduo e para prevenir a ocorrência de um evento isquêmico secundário - Google Patents
composto e sais farmaceuticamente aceitáveis do mesmo, composição farmacêutica, e, métodos para tratar trombose em um indivìduo e para prevenir a ocorrência de um evento isquêmico secundárioInfo
- Publication number
- BRPI0516181A BRPI0516181A BRPI0516181-9A BRPI0516181A BRPI0516181A BR PI0516181 A BRPI0516181 A BR PI0516181A BR PI0516181 A BRPI0516181 A BR PI0516181A BR PI0516181 A BRPI0516181 A BR PI0516181A
- Authority
- BR
- Brazil
- Prior art keywords
- individual
- pharmaceutically acceptable
- methods
- pharmaceutical composition
- treating thrombosis
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Surgery (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
COMPOSTO E SAIS FARMACEUTICAMENTE ACEITáVEIS DO MESMO, COMPOSIçãO FARMACêUTICA, E, MéTODOS PARA TRATAR TROMBOSE EM UM INDIVìDUO E PARA PREVENIR A OCORRêNCIA DE UM EVENTO ISQUêMICO SECUNDáRIO. São providas benzoxazin-4(3H)-onas substituídas, que são úteis para tratar trombose e para reduzir a probabilidade e/ou severidade de um evento isquêmico secundário em um paciente.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61456404P | 2004-09-29 | 2004-09-29 | |
PCT/US2005/034246 WO2006039212A2 (en) | 2004-09-29 | 2005-09-26 | Substituted 2h-1,3-benzoxazin-4(3h)-ones |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0516181A true BRPI0516181A (pt) | 2008-08-26 |
Family
ID=36142983
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0516181-9A BRPI0516181A (pt) | 2004-09-29 | 2005-09-26 | composto e sais farmaceuticamente aceitáveis do mesmo, composição farmacêutica, e, métodos para tratar trombose em um indivìduo e para prevenir a ocorrência de um evento isquêmico secundário |
Country Status (14)
Country | Link |
---|---|
US (1) | US7205296B2 (pt) |
EP (1) | EP1812429A4 (pt) |
JP (1) | JP2008514703A (pt) |
KR (1) | KR20070064356A (pt) |
CN (1) | CN101031565B (pt) |
AU (1) | AU2005292314B2 (pt) |
BR (1) | BRPI0516181A (pt) |
CA (1) | CA2581638A1 (pt) |
HK (1) | HK1111414A1 (pt) |
IL (1) | IL182180A0 (pt) |
MX (1) | MX2007003836A (pt) |
NZ (1) | NZ554211A (pt) |
WO (1) | WO2006039212A2 (pt) |
ZA (1) | ZA200702688B (pt) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7834023B2 (en) | 2006-09-20 | 2010-11-16 | Portola Pharmaceuticals, Inc. | Substituted dihydroquinazolines as platelet ADP receptor inhibitors |
US7740693B2 (en) | 2007-10-01 | 2010-06-22 | Honeywell International Inc. | Organic fluorescent sulfonyl ureido benzoxazinone pigments |
US9630929B2 (en) | 2011-10-31 | 2017-04-25 | Xenon Pharmaceuticals Inc. | Benzenesulfonamide compounds and their use as therapeutic agents |
WO2013064984A1 (en) | 2011-10-31 | 2013-05-10 | Xenon Pharmaceuticals Inc. | Biaryl ether sulfonamides and their use as therapeutic agents |
EA026393B1 (ru) * | 2012-05-22 | 2017-04-28 | Дженентек, Инк. | N-замещенные бензамиды и их применение в лечении боли |
KR101663436B1 (ko) | 2012-07-06 | 2016-10-06 | 제넨테크, 인크. | N-치환된 벤즈아미드 및 이의 사용 방법 |
US9469654B2 (en) | 2012-09-27 | 2016-10-18 | Portola Pharmaceuticals, Inc. | Bicyclic oxa-lactam kinase inhibitors |
EP2968280A4 (en) | 2013-03-14 | 2016-08-10 | Genentech Inc | SUBSTITUTED TRIAZOLOPYRIDINES AND METHOD OF USE THEREOF |
WO2014144545A2 (en) | 2013-03-15 | 2014-09-18 | Genentech, Inc. | Substituted benzoxazoles and methods of use thereof |
EP3450428A1 (en) | 2013-11-27 | 2019-03-06 | Genentech, Inc. | Substituted benzamides and methods of use thereof |
US10005724B2 (en) | 2014-07-07 | 2018-06-26 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
SG11201700777VA (en) | 2014-08-04 | 2017-02-27 | Nuevolution As | Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases |
RU2020134082A (ru) | 2014-10-06 | 2020-11-27 | Вертекс Фармасьютикалз Инкорпорейтед | Модуляторы регулятора трансмембранной проводимости при муковисцидозе |
MD3259253T2 (ro) | 2015-02-16 | 2020-06-30 | Univ Queensland | Sulfoniluree și compuși înrudiți și utilizări ale acestora |
KR20180008761A (ko) | 2015-05-22 | 2018-01-24 | 제넨테크, 인크. | 치환된 벤즈아미드 및 이의 이용 방법 |
WO2017035271A1 (en) | 2015-08-27 | 2017-03-02 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
CA2999769A1 (en) | 2015-09-28 | 2017-04-06 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
EP3380466A1 (en) | 2015-11-25 | 2018-10-03 | Genentech, Inc. | Substituted benzamides useful as sodium channel blockers |
JP2019513714A (ja) | 2016-03-30 | 2019-05-30 | ジェネンテック, インコーポレイテッド | 置換ベンズアミド及びその使用方法 |
PL3436446T3 (pl) | 2016-03-31 | 2023-09-11 | Vertex Pharmaceuticals Incorporated | Modulatory mukowiscydozowego przezbłonowego regulatora przewodnictwa |
SI3519401T1 (sl) | 2016-09-30 | 2022-01-31 | Vertex Pharmaceuticals Incorporated | Modulator regulatorja transmembranske prevodnosti pri cistični fibrozi, farmacevtski sestavki, postopki zdravljenja in proces za izdelavo modulatorja |
CA3039853A1 (en) | 2016-10-17 | 2018-04-26 | Genentech, Inc. | Therapeutic compounds and methods of use thereof |
DK3551622T3 (da) | 2016-12-09 | 2020-11-23 | Vertex Pharma | Modulator af transmembrankonduktansregulator af cystisk fibrose, farmaceutiske sammensætninger, behandlingsfremgangsmåder og fremgangsmåde til fremstilling af modulatoren |
JP2020511511A (ja) | 2017-03-24 | 2020-04-16 | ジェネンテック, インコーポレイテッド | ナトリウムチャネル阻害剤としての4−ピペリジン−n−(ピリミジン−4−イル)クロマン−7−スルホンアミド誘導体 |
EP3634402A1 (en) | 2017-06-08 | 2020-04-15 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
TWI789401B (zh) | 2017-07-07 | 2023-01-11 | 愛爾蘭商英弗雷佐姆有限公司 | 新穎化合物 |
AU2018304168B2 (en) | 2017-07-17 | 2023-05-04 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
AR112467A1 (es) | 2017-08-02 | 2019-10-30 | Vertex Pharma | Procesos para preparar compuestos |
US11926600B2 (en) | 2017-08-15 | 2024-03-12 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors |
UY37848A (es) | 2017-08-15 | 2019-03-29 | Inflazome Ltd | Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3 |
UY37847A (es) | 2017-08-15 | 2019-03-29 | Inflazome Ltd | Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3 |
CA3078945A1 (en) | 2017-10-09 | 2019-04-18 | Nuvation Bo Inc. | Heterocyclic compounds and uses thereof |
EP3694861A4 (en) | 2017-10-09 | 2021-05-19 | Nuvation Bio Inc. | HETEROCYCLIC COMPOUNDS AND THEIR USES |
AU2018351533B2 (en) | 2017-10-19 | 2023-02-02 | Vertex Pharmaceuticals Incorporated | Crystalline forms and compositions of CFTR modulators |
MX2020005753A (es) | 2017-12-08 | 2020-08-20 | Vertex Pharma | Procesos para producir moduladores de regulador de conductancia transmembranal de fibrosis quistica. |
TWI810243B (zh) | 2018-02-05 | 2023-08-01 | 美商維泰克斯製藥公司 | 用於治療囊腫纖化症之醫藥組合物 |
TW202000651A (zh) | 2018-02-26 | 2020-01-01 | 美商建南德克公司 | 治療性組成物及其使用方法 |
EP3759077A1 (en) | 2018-03-02 | 2021-01-06 | Inflazome Limited | Novel compounds |
CN111936494A (zh) | 2018-03-30 | 2020-11-13 | 豪夫迈·罗氏有限公司 | 作为钠通道抑制剂的取代的氢-吡啶并-吖嗪 |
EP3774825A1 (en) | 2018-04-13 | 2021-02-17 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator |
US20220162229A1 (en) * | 2019-04-09 | 2022-05-26 | Nuvation Bio Inc. | Heterocyclic compounds and uses thereof |
BR112021019703A2 (pt) | 2019-04-09 | 2021-12-14 | Nuvation Bio Inc | Compostos heterocíclicos e usos dos mesmos |
EP3952878A4 (en) * | 2019-04-09 | 2023-01-04 | Nuvation Bio Inc. | HETEROCYCLIC COMPOUNDS AND USES THEREOF |
WO2021115380A1 (zh) * | 2019-12-10 | 2021-06-17 | 上海挚盟医药科技有限公司 | 一类具有神经保护作用的化合物及其制备方法和用途 |
MX2022007265A (es) | 2019-12-20 | 2022-09-09 | Nuevolution As | Compuestos activos frente a receptores nucleares. |
WO2021198955A1 (en) | 2020-03-31 | 2021-10-07 | Nuevolution A/S | Compounds active towards nuclear receptors |
JP2023519605A (ja) | 2020-03-31 | 2023-05-11 | ヌエヴォリューション・アクティーゼルスカブ | 核内受容体に対して活性な化合物 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI101150B (fi) * | 1991-09-09 | 1998-04-30 | Sankyo Co | Menetelmä lääkeaineina käyttökelpoisten tetrahydrotienopyridiinin johd annaisten valmistamiseksi |
FR2702477B1 (fr) * | 1993-03-08 | 1995-04-28 | Synthelabo | Dérivés de benzoxazine, leur préparation et leur application en thérapeutique. |
JP3814742B2 (ja) * | 1996-10-18 | 2006-08-30 | イハラケミカル工業株式会社 | 4−フルオロサリチル酸類 |
SE9702774D0 (sv) | 1997-07-22 | 1997-07-22 | Astra Pharma Prod | Novel compounds |
CA2318199A1 (en) | 1998-01-15 | 1999-07-22 | Cor Therapeutics, Inc. | Platelet adp receptor inhibitors |
US6248729B1 (en) * | 1998-06-17 | 2001-06-19 | Bristol-Myers Squibb Co. | Combination of an ADP-receptor blocking antiplatelet drug and antihypertensive drug and a method for preventing a cerebral infarction employing such combination |
US6509348B1 (en) * | 1998-11-03 | 2003-01-21 | Bristol-Myers Squibb Company | Combination of an ADP-receptor blocking antiplatelet drug and a thromboxane A2 receptor antagonist and a method for inhibiting thrombus formation employing such combination |
US6906063B2 (en) * | 2000-02-04 | 2005-06-14 | Portola Pharmaceuticals, Inc. | Platelet ADP receptor inhibitors |
ATE309999T1 (de) * | 2000-02-04 | 2005-12-15 | Portola Pharm Inc | Blutplättchen-adp-rezeptor-inhibitoren |
JP3519078B2 (ja) * | 2000-11-01 | 2004-04-12 | 山之内製薬株式会社 | 抗血小板剤スクリーニング方法 |
US6861424B2 (en) * | 2001-06-06 | 2005-03-01 | Schering Aktiengesellschaft | Platelet adenosine diphosphate receptor antagonists |
US20060040931A1 (en) * | 2002-12-06 | 2006-02-23 | Toray Industries, Inc. | Benzomorpholine derivatives |
AU2004279809B2 (en) * | 2003-10-03 | 2010-07-15 | Portola Pharmaceuticals, Inc. | Substituted isoquinolinones |
AU2004278030C1 (en) * | 2003-10-03 | 2010-12-02 | Portola Pharmaceuticals, Inc. | 2,4-Dioxo-3-quinazolinylaryl sulfonylureas |
-
2005
- 2005-09-26 EP EP05798632A patent/EP1812429A4/en not_active Withdrawn
- 2005-09-26 ZA ZA200702688A patent/ZA200702688B/en unknown
- 2005-09-26 JP JP2007534673A patent/JP2008514703A/ja not_active Ceased
- 2005-09-26 WO PCT/US2005/034246 patent/WO2006039212A2/en active Application Filing
- 2005-09-26 AU AU2005292314A patent/AU2005292314B2/en not_active Ceased
- 2005-09-26 MX MX2007003836A patent/MX2007003836A/es active IP Right Grant
- 2005-09-26 BR BRPI0516181-9A patent/BRPI0516181A/pt not_active IP Right Cessation
- 2005-09-26 KR KR1020077009902A patent/KR20070064356A/ko not_active Application Discontinuation
- 2005-09-26 US US11/236,051 patent/US7205296B2/en active Active
- 2005-09-26 CN CN2005800328848A patent/CN101031565B/zh not_active Expired - Fee Related
- 2005-09-26 NZ NZ554211A patent/NZ554211A/en not_active IP Right Cessation
- 2005-09-26 CA CA002581638A patent/CA2581638A1/en not_active Abandoned
-
2007
- 2007-03-26 IL IL182180A patent/IL182180A0/en unknown
-
2008
- 2008-02-22 HK HK08102004.2A patent/HK1111414A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
ZA200702688B (en) | 2008-06-25 |
WO2006039212A2 (en) | 2006-04-13 |
US20060069093A1 (en) | 2006-03-30 |
CN101031565B (zh) | 2010-09-29 |
KR20070064356A (ko) | 2007-06-20 |
MX2007003836A (es) | 2007-08-20 |
HK1111414A1 (en) | 2008-08-08 |
AU2005292314A1 (en) | 2006-04-13 |
CN101031565A (zh) | 2007-09-05 |
EP1812429A4 (en) | 2010-07-21 |
IL182180A0 (en) | 2007-07-24 |
JP2008514703A (ja) | 2008-05-08 |
EP1812429A2 (en) | 2007-08-01 |
AU2005292314B2 (en) | 2011-11-03 |
WO2006039212A3 (en) | 2007-01-25 |
NZ554211A (en) | 2010-10-29 |
CA2581638A1 (en) | 2006-04-13 |
US7205296B2 (en) | 2007-04-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0516181A (pt) | composto e sais farmaceuticamente aceitáveis do mesmo, composição farmacêutica, e, métodos para tratar trombose em um indivìduo e para prevenir a ocorrência de um evento isquêmico secundário | |
MX2023002195A (es) | Compuestos y metodos para el tratamiento de infecciones virales. | |
EA200800006A1 (ru) | Триазолопиридины в качестве ингибиторов 11-бета-гидроксистероиддегидрогеназы типа i | |
ECSP067076A (es) | Derivados de pirimidina urea como inhibidores de la quinasa | |
MA29799B1 (fr) | Administration d'inhibiteurs de dipeptidyl peptidase | |
WO2007103694A3 (en) | Triazine 11-beta hydroxysteroid dehydrogenase type i inhibitors | |
BRPI0507628A (pt) | composto ou sal farmaceuticamente aceitável do mesmo, método de tratamento de uma infecção viral em um ser humano, uso de um composto composição farmacêutica, e, processo para a preparação de um composto | |
BRPI0413821A (pt) | composto ou seus sais farmaceuticamente aceitáveis, composição farmacêutica, inibidor de gsk-3, e, agente para tratar ou prevenir um doença mediada por gsk-3 | |
CR20210608A (es) | Pirroles tricíclicos condensados como moduladores de alfa-1 antitripsina | |
NO20080187L (no) | Aspartylproteaseinhibitorer | |
NO20090144L (no) | Heterosykliske aspartylproteaseinhibitorer | |
TW200736229A (en) | Substituted 1H-benzimidazole-4-carboxamides are potent PARP inhibitors | |
NO20090628L (no) | Pyridizinon derivativater | |
BR0311375A (pt) | Composição farmacêutica, uso da mesma, e, método para o tratamento de demência ou dano cognitivo suave em um mamìfero | |
BRPI0417697A (pt) | inibidores de protease de aspartila heterocìclicos | |
TW200716116A (en) | Heteroaryl 11-beta hydroxysteroid dehydrogenase type I inhibitors | |
NO20052493D0 (no) | Selekterte CGRP antagonister, fremgangsmater for fremstilling derav og deres anvendelse som farmasoytiske sammensetninger. | |
BRPI0508758B8 (pt) | composição de cloridrato de oxicodona apresentatando menos do que100 ppm de 14 - hidroxicodeinona, e seus processos de preparação | |
PT2383271E (pt) | Aminoquinolonas como inibidores de gsk-3 | |
MA30725B1 (fr) | Administration d'inhibiteurs de la dipeptidyl peptidase | |
ATE531721T1 (de) | Cyanoaminochinolone als gsk-3-inhibitoren | |
BRPI0514133A (pt) | compostos de fórmula i, processo para a sua fabricação, composições farmacêuticas, método para o tratamento e/ou profilaxia de doença que são mediadas por inibidores de cetp e uso dos compostos de fórmula i | |
WO2005084654A3 (en) | Methods and compositions for treating or preventing psychiatric disorders with cox-2 inhibitors alone and in combination with antidepressant agents | |
NO20083923L (no) | Pyrazolkinoloner er potente parp-inhibitorer | |
ATE490958T1 (de) | Als agonisten für den nikotinischen acetylcholinrezeptor geeignete azabicycloalkanderivate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 8A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2260 DE 29/04/2014. |